Rubius Therapeutics
OverviewSuggest Edit
Rubius Therapeutics is developing Red-Cell Therapeutics™ (RCTs™) as a new class of medicines to address a wide array of indications, with leading applications in cancer, rare and autoimmune disease, as well as additional potential in hemophilia, infectious and metabolic diseases.
| Type | Public | |
| Founded | 2013 | |
| HQ | Cambridge, MA, US | Map |
| Website | rubiustx.com |
Recent NewsAll News
- Rubius Therapeutics Provides Operational Update and Outlines 2021 Objectives at the 39th Annual J.P. Morgan Healthcare Conference
- Rubius Therapeutics Reports Third Quarter 2020 Financial Results and Strong Execution Across the Pipeline
- Rubius Therapeutics Presents Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, Demonstrating its Dual Mechanism of Action
- Rubius Therapeutics Announces Preclinical Data Supporting its Lead Clinical Oncology Program, RTX-240, to be Presented at the Society for Immunotherapy of Cancer’s Annual Meeting
Key People/Management at Rubius Therapeutics
Pablo J. Cagnoni
Chief Executive Officer, Director
Christina Coughlin
Chief Medical Officer
Andrew Oh
Chief Financial Officer
Kris Elverum
Senior Vice President, Business Development and Strategy
Spencer Fisk
Senior Vice President & Chief Technical Operations Officer
Bryan Gillis
Vice President, Manufacturing
Rubius Therapeutics Office Locations
Rubius Therapeutics has offices in Cambridge and Smithfield
Cambridge, MA, US (HQ)
399 Binney St #300
Smithfield, RI, US
100 Technology Way
Rubius Therapeutics Financials and Metrics
Rubius Therapeutics Revenue
| USD | |
|---|---|
Net income (Q2, 2020) | (37.9m) |
EBIT (Q2, 2020) | (37.7m) |
Market capitalization (21-Jan-2021) | 747.7m |
Closing stock price (21-Jan-2021) | 9.2 |
Cash (30-Jun-2020) | 129.2m |
EV | 737.5m |
Rubius Therapeutics's current market capitalization is $747.7 m.
Annual
Quarterly
| USD | Q1, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|
General and administrative expense | 1.1m | 5.8m | 16.3m | 13.2m | 13.5m | 13.8m | 15.0m | 12.7m | 11.6m |
R&D expense | 3.7m | 9.7m | 12.0m | 14.4m | 20.9m | 27.5m | 33.5m | 36.2m | 26.1m |
Operating expense total | 4.8m | 15.4m | 28.2m | 27.6m | 34.4m | 41.3m | 48.5m | 48.9m | 37.7m |
EBIT | (4.8m) | (15.4m) | (28.2m) | (27.6m) | (34.4m) | (41.3m) | (48.5m) | (48.8m) | (37.7m) |
Annual
Annual
Quarterly
| USD | Q1, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | (4.9m) | (15.3m) | (44.4m) | (62.0m) | (32.6m) | (72.0m) | (119.0m) | ||
Depreciation and Amortization | 48.0k | 227.0k | 502.0k | 879.0k | 661.0k | 1.4m | 2.3m | 1.8m | 3.6m |
Accounts Payable | 937.0k | 452.0k | 3.0m | 2.4m | (966.0k) | (4.7m) | 3.2m | 905.0k | 3.1m |
Cash From Operating Activities | (3.1m) | (10.9m) | (20.8m) | (38.6m) | (22.9m) | (52.7m) | (81.5m) | (40.0m) | (68.6m) |
| USD | FY, 2016 |
|---|---|
Debt/Equity | 6.3 x |
Debt/Assets | 1.5 x |
Financial Leverage | 4.1 x |
Rubius Therapeutics Cybersecurity Score
Rubius Therapeutics Environment, Social & Governance (ESG) Ratings
Rubius Therapeutics Online and Social Media Presence
1.04k Twitter followers
Rubius Therapeutics has 1.04k Twitter Followers. The number of followers has increased 2.7% month over month and increased 5.6% quarter over quarter
Rubius Therapeutics's Trends
Twitter Engagement Stats for @rubius_tx
290
Tweets
251
Following
1k
Followers
11
Tweets last 30 days
5.3
Avg. likes per Tweet
100%
Tweets with engagement
Rubius Therapeutics News and Updates
January 11, 2021
Rubius Therapeutics Provides Operational Update and Outlines 2021 Objectives at the 39th Annual J.P. Morgan Healthcare Conference
Initial Clinical Data Show RTX-240 Stimulates Innate and Adaptive Immunity (NK Cells and T Cells) Supporting Proof of Mechanism – Additional Results to be Presented in Early 2021
November 09, 2020
Rubius Therapeutics Reports Third Quarter 2020 Financial Results and Strong Execution Across the Pipeline
Completed Dosing of Fourth Cohort in RTX-240 Phase 1/2 Solid Tumor Clinical Trial
October 28, 2020
Rubius Therapeutics Presents Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, Demonstrating its Dual Mechanism of Action
RTX-321 Induces Antigen-Specific Stimulation Combined with Broad Stimulation of Innate and Adaptive Immune Responses RTX-321 Induces Antigen-Specific Stimulation Combined with Broad Stimulation of Innate and Adaptive Immune Responses
October 15, 2020
Rubius Therapeutics Announces Preclinical Data Supporting its Lead Clinical Oncology Program, RTX-240, to be Presented at the Society for Immunotherapy of Cancer’s Annual Meeting
CAMBRIDGE, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the company will present preclinical d…
September 28, 2020
Rubius Therapeutics Appoints Jose Carmona as Chief Financial Officer
CAMBRIDGE, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced the appointment of Jose “Pepe” Carmona as …
August 10, 2020
Rubius Therapeutics Reports Second Quarter 2020 Financial Results and Positive Progress Across Pipeline
Strong Momentum in Dosing Patients and Manufacturing Clinical Supply for RTX-240 Phase 1/2 Solid Tumor Clinical Trial
Rubius Therapeutics Blogs
January 04, 2021
Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
Content Import
Mon, 01/04/2021 - 16:01
Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
January 4, 2021
This release is a bac…
November 30, 2020
Rubius Therapeutics to Participate in Evercore ISI 3rd Annual HealthCONx Conference
CAMBRIDGE, Mass. , Nov. 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J.
November 20, 2020
Rubius Therapeutics Named to the List of Top Places to Work in Massachusetts by the Boston Globe and Top 5 Best Places to Work in Rhode Island by Providence Business News
Rubius Therapeutics Named to the List of Top Places to Work in Massachusetts by the Boston Globe and Top 5 Best Places to Work in Rhode Island by Providence Business News
Brian.Hoenig@n…
Fri, 11/20/2020 - 09:27
Rubius Therapeutics Named to the List of Top Places to Work in Massachusetts by…
November 10, 2020
Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference
Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference
Content Import
Tue, 11/10/2020 - 16:02
Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference
November 10, 2020
This release is a backfill from a…
November 09, 2020
Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic™ Clinical Oncology Program, RTX-240, at the Society for Immunotherapy of Cancer’s Annual Meeting
Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic™ Clinical Oncology Program, RTX-240, at the Society for Immunotherapy of Cancer’s Annual Meeting
Content Import
Mon, 11/09/2020 - 08:02
Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic™ C…
November 09, 2020
RTX-240, an Allogeneic Engineered Red Blood Cell Expressing 4-1BBL and IL-15TP, Promotes NK Cell Functionality In Vitro and In Vivo
Anne-Sophie Dugast, Shannon L. McArdel, Enping Hong, Arjun Bollampalli, Maegan E. Hoover, Sneha Pawar, Viral Amin, Kangjian Qiao, Christopher Ta, Laurence A. Turka, Thomas J. Wickham, Sivan Elloul SITC 2020 RTX-240 Audio Recording Your browser does not support the audio element.
The post RTX-240, an…
Rubius Therapeutics Frequently Asked Questions
When was Rubius Therapeutics founded?
Rubius Therapeutics was founded in 2013.
Who are Rubius Therapeutics key executives?
Rubius Therapeutics's key executives are Pablo J. Cagnoni, Christina Coughlin and Andrew Oh.
How many employees does Rubius Therapeutics have?
Rubius Therapeutics has 174 employees.
Who are Rubius Therapeutics competitors?
Competitors of Rubius Therapeutics include ImCheck Therapeutics, Confo Therapeutics and Opthea.
Where is Rubius Therapeutics headquarters?
Rubius Therapeutics headquarters is located at 399 Binney St #300, Cambridge.
Where are Rubius Therapeutics offices?
Rubius Therapeutics has offices in Cambridge and Smithfield.
How many offices does Rubius Therapeutics have?
Rubius Therapeutics has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies